Monopar TherapeuticsvsThermo Fisher Scientific

MNPR and TMO stock compared: price, dividend, valuation and results, from SEC filings.

MNPR

Monopar Therapeutics Inc.

$69.00

Value $591M

-1.84%
MNPR's page

TMO

Thermo Fisher Scientific Inc

$669.54

Value $249B

-2.79%
TMO's page

Monopar Therapeutics (MNPR) has a market value of $591M and Thermo Fisher Scientific (TMO) $249B. Over the last year, with dividends, MNPR moved -16.9% and TMO +17.1%. Dividend yield: MNPR none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MNPR$591M

    TMO$249B

    TMO is 421 times MNPR

  • Revenue, 12 months

    MNPR$0

    TMO$47.4B

  • Net income, 12 months

    MNPR-$21M

    TMO$7.1B

  • Operating margin

    MNPR–

    TMO17.9%

  • ROIC

    MNPR-9.6%

    TMO8.2%

    17.8 points apart

  • P/E

    MNPR–

    TMO35.2

  • Dividend yield

    MNPR0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    MNPR+193.0%

    TMO+6.8%

    186.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MNPR+193.1%

TMO+6.8%

020040020222023202420252026
Returns by period
PeriodMNPRWith dividendsTMOWith dividends
1 year since November 19, 2025-16.9%Price -16.9%+17.1%Price +16.7%
3 years since November 20, 2023+4,658.6%+262.4% a yearPrice +4,658.6%+44.1%+13.0% a yearPrice +42.7%
5 years since November 19, 2021+193.0%+24.0% a yearPrice +193.0%+6.8%+1.3% a yearPrice +5.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MNPRMonopar TherapeuticsTMOThermo Fisher Scientific

Valuation

MNPRTMO
Valuation
Price$69.00$669.54
Market value$591M$249B
Enterprise value (EV)$486M$284B
P/E–35.2
P/E, 5-year median–32.7
P/B4.74.5
EV/EBIT–33.5
Free cash flow yield–3.1%

Results and growth

MNPRTMO
Results and growth
Revenue, 12 months$0$47.4B
Net income, 12 months-$21M$7.1B
Free cash flow, 12 months-$16M$7.6B
Earnings per share, 12 months-$2.44$18.96
Revenue growth, year on year–3.9%
Revenue growth a year, past–+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

MNPRTMO
Margins and returns on capital
Gross margin––
Operating margin–17.9%
Net margin–14.9%
ROIC-9.6%8.2%
ROE-15.3%13.4%

Balance sheet

MNPRTMO
Balance sheet
Cash$105M$6.1B
Total debt$357.3K$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

MNPRTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield5.9%1.2%
Shareholder yield5.9%1.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MNPR or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Monopar Therapeutics or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($249B) is about 421.0 times Monopar Therapeutics ($591M), at today's prices.

How did MNPR and TMO stock do over the last 5 years?

Since November 19, 2021, MNPR's price moved +193.0% and TMO's +5.3%. With dividends: MNPR +193.0% (+24.0% a year), TMO +6.8% (+1.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, MNPR or TMO?

The dividend yield at today's price is none for Monopar Therapeutics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which is the better investment, Monopar Therapeutics or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.